Hemophilia A Gene Therapy Offers Sustained Clinical Benefit
In men with severe hemophilia A, treatment with an adeno-associated virus serotype 5 (AAV5) vector containing a B-domain-deleted factor VIII (FVIII) gene, known as...
HCT Recipients Acquire Rare, Potentially Harmful Clonal Mutations Harbored by Younger Donors
Some patients with acute myeloid leukemia (AML) who received a hematopoietic cell transplantation (HCT) from young donors acquired rare, yet potentially harmful, clonal mutations...
Adding Isatuximab to Dexamethasone-Pomalidomide Combination Improves Progression-Free Survival in Pretreated Myeloma
Treatment with the investigational anti-CD38 monoclonal antibody isatuximab plus the combination of pomalidomide and low-dose dexamethasone (Pd) led to a median progression-free survival (PFS)...
Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting
According to a real-world analysis published in JAMA Oncology, treatment outcomes with idelalisib differed between patients with follicular lymphoma (FL) and chronic lymphocytic leukemia...
Study Finds No Benefit With Post-Induction Treatment Intensification in Children With ALL
According to results from the Children’s Oncology Group AALL0331 trial, pediatric patients with standard-risk B-cell acute lymphocytic leukemia (ALL) had a high rate of...
How Common Is Serotonin Release Assay-Negative Heparin-Induced Thrombocytopenia?
Heparin-induced thrombocytopenia (HIT), a prothrombotic drug reaction caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies, is commonly diagnosed with the platelet serotonin-release assay (SRA)...
A 42-Item Frailty Index Improves Survival Prediction in Myelodysplastic Syndromes
In a recent Leukemia paper, researchers reported on a new 42-variable frailty index (FI) for patients with myelodysplastic syndromes (MDS), which appears to improve...
Evaluating Efgartigimod in Patients With Primary Immune Thrombocytopenia
Treatment with the neonatal Fc receptor antagonist efgartigimod led to clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according...
Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive...
For patients with aggressive B-cell non-Hodgkin lymphoma (NHL) and a favorable prognosis, treatment with four cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and...
Asciminib Shows Durable Clinical Activity in Heavily Pretreated CML
In a phase I, dose-escalation study, treatment with asciminib was active and associated with durable responses in more than half of patients with chronic...
Current Issue
April 2020, Volume 6, Issue 5
This issue examines current immunization guidelines in the context of patients with hematologic disorders experiencing secondary immunodeficiency, and more.
